Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3995545 | 0.80 | PTPN1 (0.58) | MRGPRX4PPARDPTPN2PTPN1PTPN6 | |
| SCHEMBL4602156 | 0.76 | PTPN11 (0.60) | PPARDPTPN1PTPN6PTPN11SYK | |
| SCHEMBL3943762 | 0.73 | CFD (0.47) | PPARDRXRARXRBRXRG | |
| SCHEMBL3992911 | 0.73 | CFD (0.51) | PPARDRXRARXRBSYK | |
| SCHEMBL3991789 | 0.71 | PTPN1 (0.58) | MRGPRX4PTPN2PTPN1PTPN6RXRA | |
| SCHEMBL3997039 | 0.71 | CFD (0.74) | RXRARXRBRXRG | |
| SCHEMBL23226557 | 0.70 | PTPN1 (0.61) | MRGPRX4PPARDPTPN2PTPN1PTPN6 | |
| SCHEMBL3995376 | 0.69 | RXRB (0.58) | PPARDPTPN1PTPN6RXRARXRB | |
| SCHEMBL8243758 | 0.69 | LRRK2 (0.58) | MRGPRX4PPARDPTPN2PTPN1PTPN6 | |
| SCHEMBL4200632 | 0.69 | LRRK2 (0.63) | SLC6A4HTR2CHTR2BMRGPRX4RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544699-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | TFPI, F3, F2 | SLC6A4 4491/4885HTR2C 438/4885HTR2B 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.